Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: Interim analysis from an open-label, two-stage adaptive, randomized, controlled trial

Clinical Drug Investigation

Volumn 29, Issue 4, 2009, Pages 231-241

  Baron, Ralf ^a   Mayoral, Victor ^b   Leijon, Göran ^c   Binder, Andreas ^a   Steigerwald, Ilona ^d   Serpell, Michael ^e  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d GRÜNENTHAL GMBH   (Germany)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LIDOCAINE; PARACETAMOL; PREGABALIN;

ALLODYNIA; ANALGESIA; APPLICATION SITE REACTION; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE SEVERITY; DRUG CAPSULE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FURUNCULOSIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PAIN ASSESSMENT; PATIENT COMPLIANCE; PLASTER CAST; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN PAIN; TREATMENT RESPONSE;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; AGED; ANALGESICS; ANESTHETICS, LOCAL; CAPSULES; DIABETIC NEUROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LIDOCAINE; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 62949139032     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200929040-00002     Document Type: Article

References (32)

1. Cruccu G, Anand P, Attal N, et al. EFNS guidelines on neuropathic pain assessment. Eur J Neurol 2004 Mar; 11 (3): 153-62
2. Belgrade MJ. Following the clues to neuropathic pain: distribution and other leads reveal the cause and the treatment approach. Postgrad Med 1999 Nov; 106 (6): 127-32: 35-40
3. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007; 132: 237-51
4. Volpi A, Gross G, Hercogova J, et al. Current management of herpes zoster: the European view. Am J Clin Dermatol 2005; 6 (5): 317-25
5. Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Pain Med 2008; 9 (6): 660-774
6. Finnerup NB, Otto M, Jensen TS, et al. An evidence-based algorithm for the treatment of neuropathic pain. Med Gen Med 2007; 9 (2): 36
7. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005 Dec 5; 118 (3): 289-305
8. Pfizer Limited. Lyrica capsules SPC [online]. Available from URL: http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=14651 [Accessed 2009 Jan 16]
9. Dworkin RH, Corbin AE, Young Jr JP, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003 Apr 22; 60 (8): 1274-83
10. Sabatowski R, Galvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 2004 May; 109 (1-2): 26-35
11. van Seventer R, Feister HA, Young Jr JP, et al. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin 2006 Feb; 22 (2): 375-84
12. Lesser H, Sharma U, LaMoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy. Neurology 2004; 63: 2104-10
13. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005; 6: 253-60
14. Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004 Aug; 110 (3): 628-38
15. Galer BS, Rowbotham MC, Perander J, et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999 Apr; 80 (3): 533-8
16. Khaliq W, Alam S, Puri N. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database Syst Rev 2007 (2): CD004846
17. Rowbotham MC, Davies PS, Verkempinck C, et al. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996 Apr; 65 (1): 39-44
18. Argoff CE, Galer BS, Jensen MP, et al. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale. Curr Med Res Opin 2004; 20 Suppl. 2: S21-8
19. Herrmann DN, Barbano RL, Hart-Gouleau S, et al. An open-label study of the lidocaine patch 5% in painful idiopathic sensory polyneuropathy. Pain Med 2005; 6: 379-84
20. Barbano RL, Herrmann DN, Hart-Gouleau S, et al. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol 2004 Jun; 61 (6): 914-8
21. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005 Jan; 113 (1-2): 9-19
22. Sindrup SH, Bach FW, Madsen C, et al. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 2003 Apr 22; 60 (8): 1284-9
23. Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain 2004 Apr; 108 (3): 248-57
24. Bauer P, Köhne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994; 50 (4): 1029-41
25. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985 Apr-Jun; 4 (2): 213-26
26. Cochran W. Some methods for strengthening the common X2 tests. Biometrics 1954; 10: 31
27. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959 Apr; 22 (4): 719-48
28. Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 2003 Nov; 106 (1-2): 151-8
29. Galer BS, Jensen MP, Ma T, et al. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clin J Pain 2002; 18 (5): 297-301
30. Baron R, Binder A, Boesl I, et al. Long-term efficacy, safety and quality of life with lidocaine 5% medicated plaster in post-herpetic neuralgia [abstract no. 787]. Pain in Europe V, 5th Congress of the European Federation of IASP chapters (EFIC); 2006 Sep 13-16; Istanbul
31. Hans G, Baron R, Binder A, et al. Long-term efficacy and tolerability of a 5% lidocaine-medicated plaster for the topical treatment of post-herpetic neuralgia: results of a long-term study [abstract no. 2894]. 12th World Congress on Pain; 2008 Aug 17-22; Glasgow
32. Glasser SP, Salas M, Delzell E. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems. J Clin Pharmacol 2007 Sep; 47 (9): 1074-86